Name: PT-141
Brand: Amino Club
SKU: PT-141 - 10MG
Availability: InStock
Rating: 4.9 (67 reviews)

PT-141 | 99%+ Pure Peptide | Amino Club | Amino Club

Frequently Asked Questions

Common questions about PT-141 research

PT-141 (Bremelanotide) is a cyclic heptapeptide that is the active metabolite of Melanotan II (MT-II). When the body processes Melanotan II, it removes the C-terminal amide group to create PT-141. This modification focuses the peptide's activity on melanocortin receptors MC3R and MC4R involved in sexual function, while reducing the tanning (melanogenesis) effects associated with MT-II. PT-141 is FDA-approved as Vyleesi for treating hypoactive sexual desire disorder in premenopausal women.

PT-141 works through a completely different mechanism than PDE5 inhibitors like Viagra (sildenafil) or Cialis (tadalafil). While PDE5 inhibitors work on blood vessels to improve erection by enhancing blood flow, PT-141 works in the central nervous system by activating melanocortin receptors in the hypothalamus to enhance sexual desire itself. This makes PT-141 a potential option for individuals who don't respond to PDE5 inhibitors, as it addresses the psychological/neurological component of sexual function rather than just the physical response.

Two identical Phase 3 trials (RECONNECT) enrolled 1,247 premenopausal women with hypoactive sexual desire disorder. Women received bremelanotide 1.75 mg subcutaneously as needed for 24 weeks. Both studies showed statistically significant improvements in sexual desire (measured by FSFI-D: +0.30 to +0.42 points, P<.001) and significant reductions in distress related to low sexual desire (FSDS-DAO: -0.29 to -0.37 points, P<.005) compared to placebo. These results led to FDA approval in June 2019.

PT-141 is FDA-approved only for premenopausal women with HSDD (as Vyleesi). It is not approved for use in men. However, it has been studied in men with erectile dysfunction, including those who did not respond to PDE5 inhibitors, and showed efficacy through its CNS mechanism. For men, PT-141 remains a research compound and is not FDA-approved for any male indication.

PT-141 is administered as a subcutaneous injection at least 45 minutes before anticipated sexual activity. The FDA-approved dose is 1.75 mg, with a maximum of one dose per 24 hours and no more than 8 doses per month recommended. It is available as a single-dose auto-injector (Vyleesi) for home use. The injection is typically given in the abdomen or thigh.

The most common side effects in clinical trials were nausea (40%), flushing (20%), injection site reactions (13%), and headache (11%). Most adverse events were mild to moderate. PT-141 may also cause temporary increases in blood pressure and decreases in heart rate, which is why it's contraindicated in uncontrolled hypertension. Focal hyperpigmentation (skin darkening) has also been reported and may not fully resolve after stopping treatment.

PT-141 typically begins working within 45-60 minutes after subcutaneous injection, with peak effects occurring around 2 hours. The effects may last up to 24 hours. This is why it's recommended to administer the injection at least 45 minutes before anticipated sexual activity. The half-life is approximately 2.7 hours.

Yes, PT-141 can cause focal hyperpigmentation (darkening of skin), though this effect is less pronounced than with Melanotan II. In clinical trials, hyperpigmentation of the face, gums, and breasts was reported. This darkening may not fully resolve after discontinuing the medication. If you develop new or worsening dark spots while using PT-141, you should consult a healthcare provider.

PT-141

Frequently Researched Together

NAD+

Central Nervous System Action

Melanocortin-4 Receptor

Melanocortin-3 Receptor

Nitric Oxide Pathway

Brain-Based Action

Melanotan II Derivative

Improvement in Sexual Desire (FSFI-D Score)

Key Regulatory & Clinical Achievements

Enhancement of Desire

Erectile Function Research

Rapid Effect

Central vs Peripheral

Nausea

Flushing

Headache

Injection Site Reactions

Blood Pressure Changes

Discontinuation Rates

Contraindications

💡Researcher Notes

What Is PT-141?

Stability Information

Regulatory Information

What is PT-141 and how is it related to Melanotan II?

How does PT-141 differ from Viagra or Cialis?

What did the clinical trials show?

Is PT-141 approved for use in men?

How is PT-141 administered?

What are the main side effects?

How quickly does PT-141 work?

Can PT-141 cause skin darkening like Melanotan II?

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

PT-141: a melanocortin agonist for the treatment of sexual dysfunction

An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist

Safety Profile of Bremelanotide Across the Clinical Development Program

Vyleesi (bremelanotide) Prescribing Information

Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder

Bremelanotide - Compound Summary (CID 9941379)

⚠️Important Research Notice

All the research peptides you need, with the peace of mind and research community at your fingertips.

Stay Updated with Amino Club

Frequently Researched Together

NAD+

Researcher Notes